🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for High-risk Melanoma

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. NCT07092670n/a10 sites📍 Bari📍 Genova📍 Milan Intergruppo Melanoma Italiano · Tests: Dabrafenib + Trametinib, Pembrolizumab, Nivolumab, Observation Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma NCT07501117Phase 11 site📍 Herlev Inge Marie Svane · Tests: Nivolumab & Ipilimumab Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma NCT06240143Phase 1, Phase 26 sites📍 Amsterdam📍 Amsterdam📍 Groningen The Netherlands Cancer Institute · Tests: Ipilimumab, Nivolumab, Nivolumab 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites📍 Kingswood📍 Wollongong📍 Southport Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD204 Modified Vaccine for High Risk or Low Residual Melanoma Patients NCT01898039Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: A2/4-1BBL melanoma vaccine, DNP sensititzation, Cyclophosphamide Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma NCT00040352n/a2 sites📍 Bethesda📍 Bethesda National Cancer Institute (NCI) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Adjuvant Tebentafusp in High Risk Ocular Melanoma NCT06246149Phase 315 sites📍 Lake Success📍 Brussels📍 Nice European Organisation for Research and Treatment of Cancer … · Tests: Tebentafusp Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042Phase 1, Phase 26 sites📍 Scottsdale📍 Denver📍 New Haven Simcha IL-18, Inc. · Tests: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer NCT05463796n/a1 site📍 Boston Dana-Farber Cancer Institute · Tests: Samples Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma NCT06319196Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Opdualag, Nivolumab A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. NCT07448831Phase 21 site📍 Jette Universitair Ziekenhuis Brussel · Tests: Pembrolizumab Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK) NCT07524114n/a1 site📍 Toronto University Health Network, Toronto DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Atezolizumab NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma NCT06889766Phase 12 sites📍 Lausanne📍 Lausanne Centre Hospitalier Universitaire Vaudois · Tests: NY-ESO-1 TCR redirected autologous T cell product, Low-dose irradiation, Non-myeloablative lymphodepleting chemotherapy Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908Phase 22 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma NCT07680699n/a1 site📍 São Paulo AC Camargo Cancer Center · Tests: Anti-PD1 Therapy Timing A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies NCT04114136Phase 21 site📍 Pittsburgh Dan Zandberg · Tests: Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites📍 New Haven📍 Atlanta📍 Grand Rapids Pliant Therapeutics, Inc. · Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) NCT02332668Phase 1, Phase 216 sites📍 Aurora📍 Chicago📍 Boston Merck Sharp & Dohme LLC · Tests: Pembrolizumab A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma NCT03116412NA20 sites📍 Borås📍 Eskilstuna📍 Falun Uppsala University · Tests: CT or PET scans Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496Phase 1, Phase 23 sites📍 Gilbert📍 Tucson📍 Seattle University of Arizona · Tests: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies NCT05053555NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: high dose rate brachytherapy, high dose rate brachytherapy An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors NCT06942143Phase 11 site📍 Guangzhou Guangzhou FineImmune Biotechnology Co., LTD. · Tests: Super1 TCR-T Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition NCT07680452NA1 site📍 Berlin Charite University, Berlin, Germany · Tests: High-Fiber Diet, High-Fiber Diet and Short-Term Fasting High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial NCT06298734NA2 sites📍 Boston📍 Seattle Fred Hutchinson Cancer Center · Tests: Exercise Program, Diet Program Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) NCT06630611Phase 21 site📍 Barcelona Vall d'Hebron Institute of Oncology · Tests: NMA-LD regimen, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2, IL-2 analog
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy